Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors

I-Rue Lai; Rey-Heng Hu; King-Jen Chang

Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors

Hepatogastroenterology. 2005 May-Jun;52(63):826-8.

Authors

I-Rue Lai¹, Rey-Heng Hu, King-Jen Chang

Affiliation

¹ Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. irlai@ha.mc.ntu.edu.tw

PMID: 15966213

Abstract

Imatinib, an inhibitor of the tyrosine kinase activity of c-kit, was used as an adjuvant chemotherapy in two patients who underwent curative surgery for recurrent gastrointestinal stromal tumors. One patient has maintained tumor-free survival for 12 months, while the other had rapid recurrence and metastasis of tumors 3 months after he discontinued the drug. The indication and effects of imatinib for prevention of recurrence of GIST after ablative surgery were discussed.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Benzamides
Chemotherapy, Adjuvant
Combined Modality Therapy
Gastrointestinal Stromal Tumors / diagnostic imaging
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / surgery
Humans
Ileal Neoplasms / drug therapy*
Ileal Neoplasms / surgery
Imatinib Mesylate
Jejunal Neoplasms / diagnostic imaging
Jejunal Neoplasms / drug therapy*
Jejunal Neoplasms / surgery
Male
Middle Aged
Neoplasm Recurrence, Local / diagnostic imaging
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / surgery
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate